ARDELYX, INC.
ARDXNasdaq
$5.20
↑ +1.5%Jul 17 close · end-of-day
Price
1Y↑ +13.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.3B
Enterprise Value
$1.2B
P/E
—
P/S
3.0
P/B
8.6
EV/EBITDA
—
PEG
—
FCF Yield
-2.9%
Dividend Yield
—
Revenue (TTM)
$427.7M
Net Income (TTM)
-$58.5M
Free Cash Flow (TTM)
-$37.5M
Gross Margin
—
Operating Margin
-8.8%
Net Margin
-13.7%
ROE
-39.3%
ROIC
-25.9%
Debt / Equity
1.4
Net Cash
$34.6M
Return 1Y
+15.0%
Company profile
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation. It is also developing RDX013, a potassium secretagogue, for the. treatment of elevated serum potassium, or hyperkalemia, among certain patients with kidney and/or heart disease.
- CEO
- Michael G. Raab
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- California
- Website
- ardelyx.com
Management & directors
- Raab MichaelPresident & CEO
- Williams Laura AChief Patient Officer
- Bishop John ESee Remarks
- Brady James ParkerChief Human Resources Officer
- Foster Eric DuaneChief Commercial Officer
- Hohenleitner SusanChief Financial Officer
- Kelliher MikeChief Business Officer
- Reilly Joseph JamesSee Remarks
- Grammer Elizabeth ASee Remarks
- Renz Justin AChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ARDX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$94.5M↑ +27.5%
Diluted EPS-$0.15↓ -11.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.6M | $10.1M | $52.2M | $124.5M | $333.6M | $407.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$90.8M | -$154.3M | -$63.8M | -$63.3M | -$27.9M | -$41.0M |
| Net income | -$94.3M | -$158.0M | -$67.0M | -$66.0M | -$39.0M | -$62.0M |
| Diluted EPS | -$1.05 | -$1.52 | -$0.42 | -$0.30 | -$0.17 | -$0.26 |
| Operating cash flow | -$81.4M | -$152.6M | -$70.0M | -$89.7M | -$44.8M | -$42.5M |
| Free cash flow | -$81.8M | -$154.4M | -$70.1M | -$90.1M | -$45.8M | -$44.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1199.0% | -1528.6% | -122.2% | -50.8% | -8.4% | -10.1% |
| Net margin | -1245.7% | -1564.8% | -128.5% | -53.0% | -11.7% | -15.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.2M | $98.2M | $116.1M | $74.1M | $97.7M | $110.3M | $125.2M | $94.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$13.6M | $2.2M | $8.1M | -$36.3M | -$14.4M | $4.7M | $5.1M | -$32.8M |
| Net income | -$16.5M | -$809,000.00 | $4.8M | -$41.1M | -$19.1M | -$969,000.00 | -$808,000.00 | -$37.6M |
| Diluted EPS | -$0.07 | $0.00 | $0.01 | -$0.17 | -$0.08 | $0.00 | -$0.01 | -$0.15 |
| Operating cash flow | -$19.4M | $501,000.00 | $9.8M | -$38.5M | -$25.3M | $365,000.00 | $21.0M | -$32.2M |
| Free cash flow | -$19.5M | $364,000.00 | $9.2M | -$38.8M | -$26.0M | $209,000.00 | $20.6M | -$32.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -18.6% | 2.3% | 7.0% | -49.0% | -14.7% | 4.2% | 4.1% | -34.7% |
| Net margin | -22.5% | -0.8% | 4.1% | -55.5% | -19.5% | -0.9% | -0.6% | -39.8% |
Company news
Jul 20, 2026
Jun 26, 2026
Jun 24, 2026
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | RAAB MICHAEL· President & CEO | Sale | 41,668 | $5.06 | $210,923.42 | filing |
| 2026-07-15 | RAAB MICHAEL· President & CEO | Option exercise | 20,834 | $0.99 | $20,625.66 | filing |
| 2026-06-18 | Williams Laura A· Chief Patient Officer | Sale | 81,898 | $5.99 | $490,487.12 | filing |
| 2026-06-18 | Williams Laura A· Chief Patient Officer | Option exercise | 31,000 | $0.99 | $30,690.00 | filing |
| 2026-06-16 | Cadoret-Manier Onaiza | Award | 26,455 | $0.00 | $0.00 | filing |
| 2026-06-16 | Bhanji Muna | Award | 26,455 | $0.00 | $0.00 | filing |
| 2026-06-16 | Bertrand William C JR | Award | 12,345 | $0.00 | $0.00 | filing |
| 2026-06-16 | Bertrand William C JR | Award | 26,455 | $0.00 | $0.00 | filing |
| 2026-06-16 | Bazemore Robert B | Award | 26,455 | $0.00 | $0.00 | filing |
| 2026-06-16 | MOTT DAVID M | Award | 26,455 | $0.00 | $0.00 | filing |
| 2026-06-16 | Parsey Merdad | Award | 26,455 | $0.00 | $0.00 | filing |
| 2026-06-16 | Rodgers Richard J | Award | 26,455 | $0.00 | $0.00 | filing |
| 2026-06-16 | MOTT DAVID M | Award | 20,282 | $0.00 | $0.00 | filing |
| 2026-06-15 | RAAB MICHAEL· President & CEO | Sale | 41,666 | $5.67 | $236,346.22 | filing |
| 2026-06-15 | RAAB MICHAEL· President & CEO | Option exercise | 20,833 | $0.99 | $20,624.67 | filing |
| 2026-05-21 | RAAB MICHAEL· President & CEO | Sale | 17,926 | $6.27 | $112,351.21 | filing |
| 2026-05-21 | RAAB MICHAEL· President & CEO | Sale | 14,933 | $6.27 | $93,592.58 | filing |
| 2026-05-21 | RAAB MICHAEL· President & CEO | Sale | 14,028 | $6.27 | $87,920.49 | filing |
| 2026-05-21 | RAAB MICHAEL· President & CEO | Sale | 7,861 | $6.27 | $49,268.82 | filing |
| 2026-05-21 | Foster Eric Duane· Chief Commercial Officer | Sale | 3,166 | $6.27 | $19,842.91 | filing |
| 2026-05-21 | Kelliher Mike· Chief Business Officer | Sale | 2,900 | $6.27 | $18,175.75 | filing |
| 2026-05-21 | Reilly Joseph James· See Remarks | Sale | 2,683 | $6.27 | $16,815.70 | filing |
| 2026-05-21 | Kelliher Mike· Chief Business Officer | Sale | 2,478 | $6.27 | $15,530.87 | filing |
| 2026-05-21 | Foster Eric Duane· Chief Commercial Officer | Sale | 2,427 | $6.27 | $15,211.22 | filing |
| 2026-05-21 | Foster Eric Duane· Chief Commercial Officer | Sale | 2,405 | $6.27 | $15,073.34 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.